Societe Generale Upgrades PMI from "Sell" to "Hold"

PMI by 2FIRSTS.ai
Feb.14
Societe Generale Upgrades PMI from "Sell" to "Hold"
Societe Generale upgrades Philip Morris International from "sell" to "hold" amid new product launches and patent settlement.

According to Marketbeat's latest report, stock research analysts at Societe Generale have upgraded their rating on Philip Morris International (NYSE: PM) from "sell" to "hold" and issued a memo to investors on February 13th.

 

PMI released its 2023 financial report on February 8th. The report stated that iQOS will be test marketed in the United States this year. Prior to this, the company settled a global patent dispute with British American Tobacco (BAT).

 

Other research analysts have recently published reports on this stock as well. Redburn Atlantic released a research report on Philip Morris International stock on Thursday, November 16, giving it a "neutral" rating and a target price of $95.00. UBS Group, in a research report on January 23, downgraded their rating on Philip Morris International from "buy" to "sell" and reduced their target price from $105.00 to $86.50. Lastly, JPMorgan Chase Bank published a research report on November 29, raising their target price on Philip Morris International from $110.00 to $115.00 and giving the company an "overweight" rating.

 

One analyst has issued a sell rating, three analysts have issued a hold rating, and six analysts have issued a buy rating. According to data from MarketBeat.com, the consensus rating for Philip Morris International is "moderate buy" with an average target price of $107.39.

 

Notice

1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.

2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.

3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.

Copyright

This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.

This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.